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ABSTRACT: There is a shift in antimalarial drug discovery from
phenotypic screening toward target-based approaches, as more
potential drug targets are being validated in Plasmodium species.
Given the high attrition rate and high cost of drug discovery, it is
important to select the targets most likely to deliver progressible
drug candidates. In this paper, we describe the criteria that we
consider important for selecting targets for antimalarial drug
discovery. We describe the analysis of a number of drug targets in
the Malaria Drug Accelerator (MalDA) pipeline, which has
allowed us to prioritize targets that are ready to enter the drug
discovery process. This selection process has also highlighted where additional data are required to inform target progression or
deprioritization of other targets. Finally, we comment on how additional drug targets may be identified.
KEYWORDS: malaria, Plasmodium, drug discovery, molecular targets
Malaria is caused by Anopheles mosquito-transmittedprotozoan Plasmodium parasites. Five species of
Plasmodium parasites cause human disease: Plasmodium
falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. Of
these, P. falciparum is associated with the most deaths,
although infections due to P. vivax and P. knowlesi can cause
severe disease. Infection with P. vivax and P. ovale is associated
with dormant liver-stage forms (hypnozoites) that can be
activated months to years after the primary infection, leading
to relapse and recurring disease.
Malaria remains a major threat to human health, imposing a
heavy social and economic burden, particularly for people from
low- and middle-income countries. An estimated 229 million
new cases occurred in 2019, predominantly in sub-Saharan
Africa, South America, and Asia, resulting in an estimated
409 000 deaths.1 Children under five and pregnant women are
at higher risk of suffering from severe malaria that can lead to
death.
According to the WHO 2020 report on malaria, annual
mortality decreased by 60% over the period 2000 to 2019, an
unprecedented level of success that saved an estimated 7.6
million lives. However, despite the considerable progress made,
these gains have plateaued since 2015 and the Global
Technical Strategy (GTS) goals for reductions of at least
40% compared to 2015 in both disease and death by 2020 have
been missed.1 Since 2000, a variety of interventions have
helped to drive this progress, including the use of more
extensive vector control measures, reliable diagnostic tests, and
improved drug therapy. However, continued progress is
hampered by the emergence of mosquitoes resistant to current
insecticides and parasites resistant to currently used anti-
malarial drugs, especially in the Greater Mekong Subregion.2
Thus, continued investment in research and development is
needed to develop the tools required to stay ahead of
resistance and generate the progress needed to achieve the
GTS goals.
History has demonstrated that P. falciparum resistance to
widely used antimalarials inevitably emerges, limiting their
effectiveness. There is established resistance or partial
resistance to nearly all currently registered antimalarial drugs
(with the exceptions of lumefantrine and pyronaridine), and
the need for new drugs working through differentiated modes
of action is urgent. The emergence of resistance can be delayed
by combining antimalarials with different modes of action.
Therefore, the identification of new, validated drug targets is
crucial in developing novel antimalarials capable of treating
parasite populations resistant to current therapies.
The challenge is to identify new treatments that are well-
tolerated in vulnerable populations, such as pregnant women,
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children under 5, and people suffering from malnutrition or
coinfection with other pathogens. Another challenge is how
best to treat people with asymptomatic malaria and protect
vulnerable populations in endemic regions from becoming
symptomatic.3 To guide the discovery of new treatments that
tackle these challenges, clear Target Product Profiles (TPP;
descriptions of medicines) are required. These are then used to
derive Target Candidate Profiles (TCP; descriptions of
molecules) to guide the antimalarial drug discovery and
development process. In 2017, Medicines for Malaria Venture
(MMV), in discussions with the wider malaria community,
updated the TCPs (Table 1) and TPPs (Table 2)4 defined first
in 2013,5 taking into account the learnings and insights gained
in recent years. With the goal of eradicating and not just
controlling malaria, the new drug pipeline should contain, in
addition to compounds efficacious enough to treat sympto-
matic malaria, drugs able to (1) interrupt disease transmission;
(2) prevent relapsing malaria, due to hypnozoites;6,7 (3)
protect the most vulnerable patients from getting disease; and
(4) clear the malaria burden by treating asymptomatic cases of
malaria.
Phenotypic screening platforms focusing on different life
cycle stages of the parasite have been developed that can
identify hits with antimalarial activity.8−12 Targets associated
with phenotypic hits are rarely identified during the early
stages of drug discovery, which could prove a challenge to the
downstream development and optimization of these com-
pounds. Target-based drug discovery can offer several
advantages over traditional phenotypic screening:
Table 1. Target Candidate Profile (TCP) definitions
TCP Goal Definition
TCP-1 Treatment of disease (both severe and uncomplicated) and
chemoprophylaxis (protecting vulnerable populations)
Compounds active against the asexual blood stage of the Plasmodium life
cycle and active against all resistant strains
TCP-3 Anti-relapse (treatment for recurrent malaria) Compounds active against liver stage hypnozoites
TCP-4 Prophylaxis (for migratory population or outbreak prevention) Compounds active against liver stages (ideally providing protection for at
least a month)
TCP-5 Transmission blockers (prevention strategies, e.g., treatment of
asymptomatic infection)
Compounds active against parasite gametocytes
TCP-6 Transmission blockers Compounds that block transmission by targeting the insect vector
(mosquitocides / endectocides)




Ideally, a combination of TCP-1 with TCP-5 or TCP-3 in order to cure acute or uncomplicated malaria in both adults and children,
ideally given as a single oral dose. A fast-killing TCP-1 compound with parenteral administration is essential for severe malaria.
TPP-2 Chemoprotection Ideally a combination of TCP-4 and TCP-1 (for emerging infection) with the goal to treat migratory populations or prevent
outbreaks.
Figure 1. Geographical location of MalDA consortium members. MalDA, with its state-of-the-art Plasmodium-adapted technology platforms in
bioinformatics, chemo-informatics, chemo-proteomics, genetic manipulation, metabolomics, in vivo resistance evaluation, and medicinal chemistry
expertise, is at the forefront of the antimalarial drug discovery process by providing tools to accelerate the finding of new starting points for drug
discovery (www.malariaDA.org).15
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• The ability to develop target-specific biochemical assays,
allowing the identification of chemical start points of
insufficient potency to be found in a phenotypic screen.
• The possibility for alternative hit generation approaches
such as fragment and structure-based methods, virtual
screening, or screening of DNA-encoded libraries (DEL).13
• Utilization of structural information to design selectivity
against the human orthologue, when present.
• Facilitate scaffold hopping, in the event of pharmacoki-
netic or toxicological issues associated with a particular
chemical series.
• Structure-based approaches have also been used to
develop compounds with reduced potential for resistance to
emerge.14
• Knowledge of the target is also important in designing
combination treatments.
• Knowledge of the target is useful in monitoring for
resistance development during clinical trials and following
deployment.
MalDA (Malaria Drug Accelerator) is an international
consortium of 17 groups funded by the Bill & Melinda Gates
Foundation. The goal of MalDA is to identify novel drug
targets in Plasmodium, primarily by linking active compounds
to molecular targets through comprehensive mode of action
studies.15 More recently, the consortium’s mission has
expanded to include the development of target-specific assays,
hit discovery, and compound progression to early lead status.
The early lead criteria that we are adopting are those defined
by MMV. This is presented on their Web site (www.mmv.org).
MalDA members are summarized in Figure 1.
■ HOW ARE TRACTABLE DRUG TARGETS
IDENTIFIED?
Tractable antimalarial targets can be identified from several
different sources. First, they can be found by establishing the
molecular targets of phenotypic screening hits of in vitro
cultured P. falciparum asexual blood stage parasites. Target
deconvolution is carried out using a variety of approaches. The
principal route has involved in vitro resistance generation
followed by whole-genome sequencing or previously by whole-
genome microarray analysis.15,16 This strategy has proven
highly successful in identifying the molecular targets of many,
but not all, phenotypically active compounds.17−19 The
location of the mutations can give indications as to whether
and where the compound binds to the protein. Indeed, this
approach can provide important additional information such as
identifying and understanding mechanisms of resistance
associated with the target. While mechanisms of resistance
can give indications of the mode of action, they can also occur
in general resistance mechanisms, such as efflux pumps or
other modulators of drug potency.
Additional techniques are now being utilized to identify the
mechanisms of action of phenotypic actives, which are
particularly valuable when resistant parasites cannot be
selected. One of these, Thermal Proteome Profiling,20 is a
mass-spectrometry-facilitated approach that exploits the
biophysical principle that binding of a ligand induces thermal
stabilization of target proteins. Shifts in the thermal stability of
proteins within the parasite proteome are monitored in the
presence and absence of drug to identify putative targets.
Another technique, metabolomics, is used to give a broad
indication of metabolic pathways affected by drug action and
provides metabolic fingerprints of compounds acting via
previously defined modes of action.16
Once the target(s) of phenotypic hits is(are) identified by
these primary methodologies, secondary experiments are
required to validate this(these) putative target(s). Despite
the increasingly sophisticated battery of techniques available to
identify molecular targets, there are still compounds where the
target or mode of action has yet to be established. This may be
due to factors such as compounds working through
polypharmacology or targeting host proteins or targets for
which it is really difficult to raise resistance. Additionally, some
compounds also act via interaction with nonprotein targets,
which can be challenging to deconvolute.
Several targets with potential to be exploited for drug
discovery have also been suggested by literature precedent, or
through general precedence as drug targets in other disease
areas. Currently, there is considerable interest in amino acyl
tRNA synthetases as potential antimalarial targets. These
enzymes have been established as viable drug targets in a
number of different pathogens. Interestingly, a number of these
enzymes have been found to be the target of phenotypic hits in
Plasmodium using target deconvolution methods described
above.21−23 Literature-based targets, however, need careful
scrutiny since there can be a disconnect between activity
against a molecular target in a biochemical assay and activity in
cellular and animal models of disease.24 Indeed, the failure of
biochemical/enzymatic hits to translate to growth inhibition
and cytocidal activity against the parasite has been a
confounding factor in the identification of lead compounds,
not only for antimalarials but for antimicrobials in general.
Finally, fundamental research by the malaria research
community, both within and outside MalDA, has led to the
identification of numerous potential drug targets. Once again,
targets identified via this route require careful assessment prior
to embarking on expensive and time-consuming drug discovery
programs.
■ OVERVIEW OF REQUIREMENTS FOR A DRUG
TARGET
When pursuing a target prioritization program, it is important
to identify the key requirements for a drug target. We25−28 and
others29 have published articles in this area. The target must be
essential for the progression or pathophysiology of the disease;
in the case of Plasmodium, this equates to survival or
transmission of the parasite. The target also needs to be
druggable: its function needs to be modifiable by a small
molecule or biologic. In the case of malaria, this must be an
orally available small molecule, to meet the criterion of a low
cost of goods. Another important concept is target vulnerability;
this is how much and for how long it is necessary to modulate
the activity of the target to have the desired phenotypic effect.
It is very challenging to maintain high levels of pharmaco-
logical inhibition of a target for prolonged periods of time;
therefore, targets requiring relatively low levels of inhibition
and/or a short duration of action to quickly “tip” the parasites
to death are more attractive. Genetic approaches to engineer
the conditional knockdown of a desired target are important
here.30,31 Further, in the case of malaria, the rate of parasite kill
is vitally important, since patients with malaria can rapidly
become severely ill and die. Therefore, targets that require
inhibition for prolonged periods to kill a parasite should not be
pursued to treat asexual blood stage infections. For prophylaxis
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or transmission blocking, a slower rate of kill may be
acceptable.
Another important consideration is the emergence of drug
resistance, which is a major concern for anti-infectives,
including antimalarials. A target with low resistance propensity,
or no obvious bypass mechanism, is preferable. However,
understanding resistance mechanisms could lead to alternate
treatments (e.g., combination therapy) or attempts to redesign
compounds, for example to mitigate the impact of a commonly
occurring resistance mutation.32 Analysis of existing poly-
morphisms (using genomic databases of thousands of patient
isolates) could also be a consideration. A high level of
polymorphism could be indicative of higher flexibility to
accumulate protein changes and thus an increased propensity
to select resistance.
Selectivity is also a requirement, aiming to minimize off-
target liabilities that might cause drug candidates to fail later in
development. For malaria, compounds should selectively
modulate the parasite target over the host equivalent, unless
there is a biological reason why inhibition of the host
equivalent does not lead to toxicological consequences. The
latter is very difficult to predict however. Since most drug
discovery paradigms use some form of screening (usually high-
throughput) to identify chemical starting points, there also
needs to be a route to develop an appropriate assay for a drug
target. While not considered a prerequisite for choosing a
target, having access to structural information can be a major
benefit, as described above.
Some requirements are specific to malaria and must be met
for a particular target to be viable (see Table 1). For example,
several species of Plasmodium cause malaria, and having a
target that is conserved in these species enhances the
likelihood that a single treatment can be developed. There
are also different life cycle stages for the parasite, so having a
compound that can act at multiple stages is desirable.
■ PROCESS FOR TARGET PRIORITIZATION
MalDA has a large portfolio of potential drug targets. We
decided to carry out a target prioritization process for several
reasons: (1) to identify targets that have the potential to
progress into drug discovery programs; (2) to identify targets
lacking key information or validation required for progression;
(3) to efficiently prioritize future work; and (4) to disseminate
our assessment of targets more broadly to the malaria drug
discovery community. To facilitate this process, we have
generated “target cards” where the information for each
criterion is stored in summary form for each of the targets.
We designed a two-tier cascade, associated with a ranking
system to assess and prioritize targets (Table 3) based on
previously published concepts.25−29 In tier 1, the level of
genetic and chemical validation and the potential to develop
resistance were evaluated, while tier 2 encompassed drugg-
ability, TCP fit, toxicity, novelty/prior information, assay
readiness and structural information. The scoring system, while
not perfect, is a way of highlighting high-priority targets.
Certain criteria are stop/go decision points. For example, a
target that is not essential or does not fulfill one specific TPP/
TCP should not progress into drug discovery.
Tier 1. We considered three different genetic validation
methods to determine the essentiality of a Plasmodium gene.
First, the genome-wide saturation mutagenesis screen in P.
falciparum asexual blood stages identified likely dispensable
and essential genes through mutagenesis index scores (MIS)
and mutagenesis fitness scores (MFS).33 Second, homologous
recombination-mediated knockout screens in the rodent
malaria parasite P. berghei provide additional information on
likely essential genes.34 Finally, validation of the genetic
essentiality of some targets of interest was available from
conditional knockouts and knockdown experiments carried out
mostly by the Niles lab.30 In this context, conditional
knockdowns are of interest to assess target vulnerability, i.e.,
the duration and extent of reduction of target levels or activity
required to compromise parasite viability. In addition, the
presence of loss-of-function alleles in the gene in whole-
genome sequences from either population studies or in vitro
resistance selection experiments were also considered as risks.
Molecular targets scored high when the corresponding gene
was deemed to be essential by the three methods. A target was
considered to have no potential for drug discovery if viable
parasites were obtained when the gene was abolished
completely in a knockout experiment.
Table 3. Criteria for Target Prioritization
tier 1 target assessment ranking
Genetic
validation
Conditional knockout. Target vulnerability upon
conditional knock-down
high
Essential in genome-wide saturation mutagenesis
in P. falciparum and/or homologous





Compound-target pair established rigorously high
Good correlation between enzyme and cell




Irresistibleno resistance found in selections high
MIR 8−9 and no cross resistance with any drug
in clinical use or development
medium
6 < MIR < 8 and no cross resistance with any
drug in clinical use or development
low
MIR ≤ 6 and an EC50 shift > 10-fold; or evidence
of high-grade resistance-conferring SNPs in
field isolates; or enzyme not conserved across
Plasmodium species
STOP
tier 2 target assessment score
Druggability Identification of small molecule inhibitors with
drug-like physicochemical properties
high
Computational analysis of the crystal structure
or a high quality homology model
medium
TPP/TCP fit Must be active against at least two life cycle
stages at similar concentrations OR blood
stage asexual stages with a fast rate of kill
STOP/
GO
Toxicity No close orthologue present; selective small





Previous work has indicated issues with
chemistry, but potential way forward using
new information/chemistry
medium
Previous work has indicated that drug-like
inhibitors with in vivo activity can be
generated and compound(s) in late stage





Protein expressed and biochemical assay
developed for this protein or a close
orthologue
high
No P. falciparum protein expressed, but





Structure of target protein and cocrystal
structures with ligands; evidence that it can be
soaked
high
Structure of target protein, but no complex;
close orthologue with structures; potential for
chimeras
medium
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Two different levels of chemical validation are considered in
our assessment, with the highest score for chemical validation
being given to compound−target pairs that have been
rigorously established. Ideally, this should include reduced
compound susceptibility of transgenic parasites that encode
the mutations selected through drug pressuring studies and
evidence of compound inhibition of recombinant enzyme.
Targets showing good correlation between recombinant
enzyme inhibition and parasite growth inhibition over 3 log
units for a compound series were also scored for chemical
validation.
The final criterion in tier 1 is the resistance potential. First,
targets associated to compounds showing a Minimum
Inoculum for Resistance (MIR) > 8 (i.e., requiring a minimum
of 108 parasites to generate resistance) are preferable and
received the highest score, while those with a MIR ≤ 6 with a
>10-fold increase in EC50 were considered high risk and were
not recommended for drug discovery projects.35,36 In addition,
the MalariaGen database provides genome variation data on
over 7000 P. falciparum genomes, allowing us to search for the
number of SNPs, amino acid changes, and known resistance
mutations for a gene of interest (www.malariagen.net).37
Preferably, a target would have a high degree of conservation
across field isolates and across multiple Plasmodium species.
Targets scoring well for essentiality, for parasite survival, and
with a manageable resistance risk can progress to tier 2
assessment.
Tier 2. Molecular targets with known small molecule
inhibitors with drug-like properties38−40 receive the highest
possible score for druggability. In the absence of known
inhibitors, computational analysis of the crystal structure or a
high-quality homology model can also be used to assess
druggability.41 Some target classes have been extensively
investigated in the context of drug discovery in other disease
areas and therefore are expected to be druggable, for example,
kinases or bromodomains. For targets for which there is prior
drug discovery experience, it is important to leverage prior
knowledge. For those programs that have been terminated, was
this due to a fundamental issue of target biology? Or was the
chemical matter inappropriate, and if so, what is the likelihood
of overcoming this? If there is a drug discovery program
ongoing elsewhere, is there something different that can be
added? It is important not to duplicate work, particularly in a
resource-limited disease area. However, given the high attrition
rate, until a compound has reached clinical proof of concept,
backup strategies need to be considered.
The tier 2 assessment includes an evaluation of the potential
to develop selective inhibitors for the targets of interest. The
absence of a close human orthologue or the presence of known
selective inhibitors are the best indicators. When there is a
human orthologue and no known selective inhibitors, a
promising target should at least show structural evidence that
there are exploitable differences in active sites of the parasite
and the human orthologue to facilitate selective inhibitor
design. It is also possible that there are differences in biology,
which may make Plasmodium more sensitive to inhibition of
the target than the human host, particularly over the short time
scale that is required for treatment of the asexual blood stage
infection.
Finally, other issues considered here are TPP/TCP fit, the
presence of structural information, and the availability of
appropriate assay(s). For those targets where recombinant
protein is difficult to produce, phenotypic assays with
conditional knockdown parasites can be used to identify
chemical starting points, although this may miss weaker or
non-cell permeant hits.
In addition to the basic scoring system, we have decided that
we need a diverse target portfolio. For example, the amino acid
tRNA synthetases are robustly validated drug targets, but it is
important to have a degree of diversity in any drug discovery
pipeline to mitigate against the possibility of unforeseen
scientific developments deprioritizing a specific target or target
class. There is also an element of opportunities as well as
taking risks with novel targets where there is relatively little
information.
■ OUTCOME OF TRIAGING
As a result of this target prioritization process, we classified
targets as follows:
• High Priority: These are targets that have a high degree of
validation and are likely to be good drug targets. There may be
missing data that would be required prior to the progression of
these targets into a full-scale drug discovery program.
However, this is where we think resources should be
prioritized, to complete validation experiments and progress
them into drug discovery.
• Targets under Consideration: These are targets that look
promising, but additional data are required to move them to a
stage where they could be prioritized. For example, this might
be missing information on TCP fit, or a lack of chemical tools.
• New and Emerging Targets: Targets requiring significant
work focused on validation. It is important to highlight specific
experiments required to validate/invalidate particular targets.
• Deprioritized Targets: Targets where we do not think
resources are justified from a MalDA perspective. Here, there
are two separate categories: (1) invalidated targets, or those
unlikely to be inhibited by compounds capable of fulfilling one
of the MMV TCPs, and (2) those targets where there are
already several substantial development programs elsewhere.
Examples include PfATP4 (where there are multiple programs
ongoing)18 and plasmepsin X42 (see Table 4 for further
examples).
Inevitably, there is a degree of judgment and subjectivity, as
information gaps will exist for most targets, and there are many
Table 4. Examples of Deprioritized Targets for MalDA
target name (abbreviation) Pf gene ID reason for deprioritization
N-myristoyl transferase (NMT) PF3D7_1412800 slow killer, challenges with selectivity compared to the human enzyme
P-type ATPase 4 (ATP4) PF3D7_1211900 multiple series under investigation in the drug discovery pipeline
plasmepsin X PF3D7_0808200 multiple series under investigation in the drug discovery pipeline
Niemann−Pick type C1-related protein (NCR1) PF3D7_0107500 resistance risk, slow rate of kill and single-stage efficacy
dihydrofolate reductase (DHFR) PF3D7_0417200 clinically approved inhibitor; resistant parasites widespread in the field
dihydroorotate dehydrogenase (DHODH) PF3D7_0603300 multiple chemotypes have been developed, and resistance can arise readily
phosphatidyl inositol 4-kinase (PI4K) PF3D7_0509800 multiple chemotypes have been developed, and resistance can arise readily
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aspects of Plasmodium biology and host−parasite interactions
that are unknown. The ultimate proof of validation of any drug
target is a clinical proof of concept, as shown for example with
inhibitors of P. falciparum dihydrofolate reductase, dihydroor-
otate dehydrogenase, the cytochrome bc1 complex, or
phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ kinase).43
The outcome of our initial triage is shown in Figure 2. This
represents the targets that we have had the opportunity to
assess. There are other interesting targets that remain to be
assessed by our target validation process.
Tables 5 (high-priority targets) and 6 (targets under
consideration) illustrate specific details for some of the targets
in Figure 2. Target prioritization is a dynamic process
prioritization of individual targets may change as key
information becomes available. In Figure 2, we provide our
current classification of targets. However, this will change, so
we have created a Web site where this information will be
updated (www.malariaDA.org). We also invite members of the
malaria research community to suggest new targets, add to our
assessments, and provide additional information on targets
being considered by MalDA.
By way of example, we will discuss three key targets. These
are intended as general examples to illustrate our approach and
thinking, across a range of different targets, and represent a
significant focus of work from MalDA members. More
information is available in the Supporting Information and
on the Web site.
Acetyl CoA Synthetase (PfAcAS) (High Priority
Target). PfAcAS is responsible for the biosynthesis of acetyl
coenzyme A from coenzyme A and acetate. We have recently
reported the validation of this enzyme.45,46
Chemical Validation. Pantothenamides such as
MMV689258 and MMV693183 are converted into antimeta-
bolites that interfere with CoA acetylation.45 In addition, two
compounds, MMV019721 and MMV084978 (Figure 3), were
found to be active in screens against both P. falciparum asexual
blood stages (EC50 values of 460 nM and 370 nM,
respectively) and P. berghei liver stages (EC50 values of 2100
nM and 520 nM, respectively). Generation of in vitro resistance
to these compounds, followed by whole-genome sequencing,
revealed multiple mutations in the gene encoding PfAcAS.
These mutations clustered around the predicted active site of
the enzyme. PfAcAS biochemical assays indicated that all test
compounds inhibit this enzyme. Pantothenamides and
MMV019721 are competitive with respect to coenzyme A,
and MMV084978 displays a mix-inhibition mode with respect
to acetate.
Genetic Validation. Several approaches have indicated the
genetic essentiality of this enzyme. The enzyme was reported
to be essential in P. berghei34 and was predicted to have a high
likelihood to be essential in a P. falciparum piggyBac insertion
mutagenesis screen.33 Conditional knockdown of the enzyme
led to both reduced parasite viability and increased sensitivity
to pantothenamides, MMV019721, and MMV084978. In
contrast, using CRISPR/Cas9 gene editing to replace the
wild-type gene for PfAcAS with allelic variants encoding
resistance mutations led to parasites with reduced sensitivity to
pantothenamides, MMV019721, and MMV084978.
Resistance Potential. It is possible to generate parasite cell
lines in vitro that are resistant to MMV689258, MMV019721,
and MMV084978, and studies to define the MIR values are
ongoing.35 One of the pantothenamides shows an MIR of 109.
As MMV019721 and MMV084978 appear to bind to different
sites on the enzyme, each may have a different resistance
susceptibility.
Druggability. Pantothenamides, MMV019721, and
MMV084978 are small molecules that fit within typical drug-
like space. The pantothenamide MMV693183 meets all criteria
Figure 2. Current MalDA target portfolio
Table 5. Targets Ranked As High Priority
target name (abbreviation) Pf gene ID key questions next steps
serine/threonine protein
kinase, putative44 (CLK3)
PF3D7_1114700 can target be structurally
enabled?
optimization of hits; more chemical starting points
cGMP-dependent protein
kinase (PKG)
PF3D7_1436600 rate of kill with selective
inhibitor








PF3D7_0109800 resistance risk more screening/scaffold hopping to identify more start points
prolyl tRNA synthetase,
putative (ProRS)





PF3D7_0627800 resistance risk; can the
target be structurally
enabled?
proof of concept from MMV693183 first-in-human study; establish alternate lead series
from existing hits/new screens and H2L; crystal structure to guide chemistry program
isoleucinetRNA ligase,
putative (cIRS)
PF3D7_1332900 rate of kill, resistance risk generate additional chemical matter
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for a preclinical candidate and is progressing toward a first-in-
human study.
TCP fit. MMV019721 and MMV084978 are active against
both asexual blood and liver stage parasites with relatively
similar EC50 values. Pantothenamides target both asexual and
sexual blood stages but have lower activity against liver stages.
Toxicity. Pantothenamides were very well tolerated in in vivo
pharmacokinetic, efficacy, and exploratory toxicology studies.
MMV019721 and MMV084978 are at an earlier stage in the
discovery pipeline and have not been subject to a detailed
assessment of toxicity. However, there is a high degree of
selectivity at both the enzyme level (compared to human acetyl
CoA synthetase) and cellular levels (compared to HepG2
cells).
Novelty. This is a novel target for malaria. There are reports
of inhibitors of fungal AcAS enzymes.47
Assay Readiness. Both PfAcAS and HsAcAs have been
recombinantly expressed and assays developed for high-
throughput screening.
Structural Information. There is no structural information
for PfAcAS, which to date is proving challenging to crystallize,
in our hands.
As a result of all of these studies, there is strong evidence
that PfAcAS is a good drug target and is druggable. The
pantothenamide MMV693183 is currently in preclinical
development. The identification of alternate series capable of
inhibiting PfAcAS would be greatly facilitated by structural
information and information regarding inhibitor binding. More
work is also required to assess the resistance risk across
inhibitor classes. This target has now progressed into drug
discovery through MalDA-supported efforts.
Bifunctional Farnesyl/Geranylgeranyl Pyrophosphate
Synthase (F/GGPPS; High Priority Target). Bifunctional
farnesyl/geranylgeranyl pyrophosphate synthase is a key
enzyme in isoprenoid biosynthesis that synthesizes C15 and
C20 prenyl chains. Prenyl chains are the substrates of a
number of prenyltranferases resulting in isoprenoid products
essential for parasite survival.
Chemical Validation.48 MMV019313 (Figure 3) inhibits
F/GGPPS activity in enzymatic assays. Generation of in vitro
resistance to this compound, followed by whole-genome
sequencing, revealed mutations in F/GGPPS (S228T).
Overexpression of F/GGPPS in parasites was sufficient to
confer resistance to MMV019313. Overexpression of the F/
GGPPS(S228T)-GFP variant, even at moderate levels, resulted
in an 18-fold increase in the EC50 value of MMV019313.
Genetic Validation. The essentiality of this enzyme has
been demonstrated via several different approaches. The P.
berghei genome-wide screen showed it to be essential.34 The P.
falciparum PiggyBac insertion mutagenesis screen shows that
the enzyme is nonmutable in its coding sequence.33 Condi-
tional knockdown studies confirm essentiality in vitro. S288T
allelic replacement parasite lines recapitulate the resistance
phenotype of drug-selected lines. Further studies are required
to ascertain whether these changes represent indirect resistance
mechanisms as opposed to being mutations in drug targets
Resistance Potential. Parasites resistant to MMV019313
acquired a S228T mutation in this gene. A 10-fold shift in
susceptibility was observed compared to the wild type. The
MIR was determined to be 108.
Druggability. There is current confidence that drug-like
compounds can be identified. MMV019313 is a small molecule
Table 6. Targets Ranked As Under Consideration and in Assay Development and Screening Stages
target name (abbreviation) Pf gene ID key questions
cytosolic seryl-tRNA synthetase
(SerRS)
PF3D7_0717700.1 chemical starting points; TCP fit
V-Type H+ ATPase includes PF3D7_0406100, PF3D7_0806800,
PF3D7_1311900
generate chemical matter; understand resistance profile, druggability, and
TCP fit
heat shock protein 90 (HSP90) PF3D7_0708400 selectivity; more chemical starting points
adenylyl cyclase beta (AC beta) PF3D7_0802600 TCP fit; more potent inhibitors; selectivity
histone acetyltransferase GCN5
(GCN5)
PF3D7_0823300 rate of kill; chemical starting points
phosphodiesterase beta (PDEβ) PF3D7_1321500 resistance potential TCP fit; More chemical starting points; chemical tools
for validation
aminopeptidase P (APP) PF3D7_1454400 TCP fit; selectivity; chemical tools
cysteine tRNA synthetase
(CysRS)
PF3D7_1015200.1 protein expressed; development of assay; selectivity
hexose transporter (HT) PF3D7_0204700 is selectivity versus human orthologues possible? TCP fit; activity against
various life cycle stages
Figure 3. Structures of tool compounds (see text for references to
each structure)
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within the drug-like space even if it needs optimization to
become a drug, suggesting that small molecule inhibitors can
be identified.
TCP fit. MMV019313 shows asexual blood stage activity
(EC50 270 nM) and complies with TCP-1. The compound has
not yet been tested for gametocyte activity. It is not active
against liver stages.
Toxicity. Human orthologues exist, and assays are available.
MMV019313 inhibits the enzymatic activity of PfF/GGPPS
but not human FPPS or GGPPS.
Novelty. PfF/GGPPS is a validated target for malaria.
Current drugs for this target in other disease areas show poor
bioavailability and selectivity. The new tool compound is a
small molecule that is selective and has a distinct mode of
inhibition compared to current drugs.
Assay Readiness. Various assay options have been reported,
including pyrophosphate production48 and radiolabeled
methods.49
Structural Information. A crystal structure is available for
PvF/GGPPS, which allows for the generation of structural
models for other Plasmodium homologues.
The discovery of a new small molecule binding to a novel
site, with superior druggability to that of the previously
established inhibitor binding site, makes this target very
attractive.
Monoacylglycerol Lipase PfMAGL (New and Emerg-
ing). Human monoacylglycerol lipase (MAGL) catalyzes the
hydrolysis of a variety of monoglycerides into fatty acids and
glycerol. In P. falciparum, this enzyme has been reported to
play a role in processing these monoglycerides, including
palmitoyl and oleoyl glycerols.50
Chemical Validation. The natural product, salinipostin A,51
and the lipid metabolism inhibitor, orlistat (Figure 3),50 were
shown to be potent against P. falciparum asexual blood stage
W2 parasites with EC50 values of 50 nM and 280 nM,
respectively. Potent inhibition of recombinant PfMAGL using
hits from a small library of triazole−urea inhibitors strongly
correlated with in vitro antiplasmodial activity against W2
parasites.
Genetic Validation. Genetic essentiality has been shown in
the P. falciparum piggyBac screen.33
Resistance Potential. In vitro resistance selection experi-
ments with salinipostin A using a high parasite inoculum (109)
in a genetically engineered Dd2 parasite line with an increased
mutation rate (Dd2_Polδ) yielded parasites that showed 2- to
9-fold reductions in sensitivity. However, no mutations were
observed in PfMAGL in this experiment. Instead, all resistant
parasites cloned had SNPs in the “protein of relevant
evolutionary and lymphoid interest” (PRELI) domain-
containing protein of unknown function (PF3D7_1324400)
with five of six clones harboring A20V, P102L, and T145I
mutations in the coding sequence, while the sixth clone had a
point mutation in intron 1 that has an unknown impact on
expression levels. Mutations at S725Y and E507K in the V-type
H+-translocating pyrophosphatase (PF3D7_1235200) were
also observed in three out of six clones.
Druggability. Salinipostin A is a natural product, while
orlistat is prescribed for obesity. The potent activity of these
compounds against P. falciparum proliferation and recombi-
nant PfMAGL highlights the feasibility of exploring their
respective scaffolds for structure−activity relationship studies
to design specific small molecule inhibitors of PfMAGL.
However, new series that are more attractive from a medicinal
chemistry perspective would increase the druggability con-
fidence.
TCP Fit. Salinipostin A and orlistat are active against asexual
blood stages at nanomolar EC50 values. However, the activity
of these compounds against liver stage parasites and
gametocytes has yet to be investigated.
Toxicity. Salinipostin A has a selectivity index >1000 for P.
falciparum asexual blood stage parasites compared to a variety
of mammalian cell lines including human foreskin fibroblasts
(HFF), HEK293T (human kidney), U2OS (human osteo-
sarcoma), and AsPC-1 (human pancreatic adenocarcinoma).51
Novelty. This is a novel target for malaria.
Assay Readiness. There already exist platforms to study this
enzyme, including a fluorogenic substrate assay to assess the
characteristics of the recombinant PfMAGL with various
fluorogenic lipid ester substrates bearing different chain
lengths. Parasite lines overexpressing PfMAGL from an
exogenously transfected plasmid have been developed. In
addition, there is a competition assay for active site labeling of
PfMAGL and human MAGL with the broad-spectrum serine
hydrolase ABP fluorophosphonate-rhodamine (FP-Rho) to
screen compounds for their ability to compete for the active
sites of the two enzymes and identify highly potent and
selective hits.
Structural Information. The crystal structure of the human
MAGL is available (PDB: 3jw8) and a predicted PfMAGL
homology model templated on this structure has been
published.50
This target shows promise as an antimalarial target, based on
the good correlation between enzyme and parasite inhibition
and the low propensity of resistance for these inhibitors. The
availability of assays will facilitate screens to identify new
potent and selective hits. Further experiments are required to
complete the chemical and genetic validation and to assess the
TCP fit for this target.
■ FUTURE PERSPECTIVES
Phenotypic Screening. In the past 20 years, drug
discovery against malaria has largely focused on phenotypic
screening approaches, due to the relative lack of robustly
validated targets. Many of the readily available compounds in
lead-like and drug-like space have already been screened
against P. falciparum, leading to a lack of novel compound
libraries to screen, particularly those addressing novel areas of
chemical space. Therefore, an increased effort focusing on
target-based approaches is merited. In the past 10 years,
significant progress has been made in identifying and validating
potential drug targets for malaria. Information about
antimalarial drug targets is being captured in a Web site by
the International Union of Basic and Clinical Pharmacology
(https://www.guidetomalariapharmacology.org/malaria/).
It is important that the most appropriate drug targets are
carefully selected for progression into drug discovery. Despite
the success in identifying clinical candidates for malaria, we
must be mindful of the high attrition rate in clinical
development, as is seen for all drug development programs.
For infectious diseases, the typical success rate from entry to
phase 1 clinical studies to compound registration is 19−
25%.52,53 Success in drug discovery and subsequent clinical
development is highly dependent upon both the selection of
the molecular target and the properties of the compounds
progressed.
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The properties of a particular molecule will be at least in part
dependent on the druggability of the target. Key challenges in
molecular designs for antimalarial drug discovery include
compounds with a long half-life, suitable for single-dose oral
treatment and chemoprotection; oral bioavailability; stability
for storage at room temperature in tropical conditions for
extended periods; a low cost of goods; and good safety profiles.
Resistance is a key issue, particularly for asexual blood stage
infections. It is not totally clear whether resistance is solely a
function of the target or the compound or both. Some targets
are known to be particularly susceptible to mutations (for
example, dihydroorotate dehydrogenase). For targets with
several different drug binding pockets (e.g., tRNA synthetases;
due to multiple substrates), each may have a different risk of
mutation.
As well as identifying the most promising molecular targets,
we also need to identify for each target the most appropriate
hit and drug discovery strategies to derive therapies with
desired profiles. For example, fragment-based drug discovery
approaches can be useful to optimize the physicochemical
properties of molecules as they are developed.
How Do We Identify Additional Drug Targets in
Malaria? First, there are still many phenotypically identified
compounds for which the mode of action remains to be
determined. Some of these may be acting on more than one
target or acting on nonprotein targets. Compounds that
demonstrate polypharmacology may be desirable to reduce the
resistance risk; however, the design of such molecules is in its
early stages.
Second, we are investigating a “big-data” approach to
identify potential new targets. As an initial triage, we have
analyzed the P. falciparum genome and cross-referenced this
against a number of different databases (Figure 4A), to identify
targets that it might be valuable to investigate. The workflow is
as follows:
•Essentiality. To determine if the target is essential in
Plasmodium, we have used the data obtained through
saturation mutagenesis33 or functional analysis.34
•Druggability. We used the recently published method of
Wang and coauthors to assess ligand binding ability.54,55 We
extracted the 236 InterPro domains listed as ligandable and
searched PlasmoDB for proteins with these domains.
•Enzymes. We also included proteins annotated with an EC
number or predicted to catalyze a reaction because many are
known to be good drug targets. Many enzymes were also
considered ligandable using the method above (e.g., kinases).
•Mammalian Orthologue. We examined whether a human
orthologue exists using the ortholog search function within
PlasmoDB.56 The lack of a mammalian orthologue has
traditionally been considered an attractive feature for anti-
infective drug targets. However, it is important that the
presence of a human orthologue is not used as a reason for
deprioritizing a target: (1) Where there is a human orthologue,
it is very often possible to obtain high levels of selectivity (for
example, against P. falciparum dihydrofolate reductase). (2)
Sometimes there are very different levels of “vulnerability”
between a pathogen enzyme and its orthologues. (3)
Plasmodium targets for which there is not a human orthologue
are not always attractive targets. For example, many early,
postgenomic drug discovery programs were focused on
members of the nonmevalonate pathway of isoprenoid
biosynthesis,57 or other proteins targeted to the apicoplast
(including bacterial-type proteins involved in protein biosyn-
thesis), a parasite-specific organelle involved in the production
of isoprenoids.58 While it may be possible to find highly
selective inhibitors for such targets, the rate of kill may be
slower, as was the case for fosmidomycin (that targets DOXP
reductoisomerase), tetracycline, or azithromycin.59 Another
caveat is that some of these druggable parasite-specific targets,
such as enoyl-ACP reductase (FabI, PF3D7_0615100), may
only be important for the liver or sporozoite stage.60,61
This analysis suggests that there are about 300−700
potential drug targets in Plasmodium. These will have different
profiles, and inhibitors of these may fulfill different TCPs.
We then did an analysis of the malaria protein targets that
have extensive validation, including those with proof-of-
concept data in humans (Figure 4B). These include the
targets that MalDA has assessed as being high value (Figure 2),
along with targets known from current drugs and targets from
Figure 4. (A) Analysis of the P. falciparum genome categorizing
targets according to their predicted essentiality, druggability, and the
presence of mammalian orthologs. The number of proteins in each
category is shown in parentheses. (B) Analysis of high value targets,
according to tool compounds, the presence of mammalian orthologs,
and proof of concept in humans. The number of proteins in each
category is shown in parentheses. Where there is only one protein in a
category, it is stated explicitly. Most MalDA targets fall into the light
blue or violet regions.
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compounds currently in clinical development, including PI4K,
eEF2, and DHODH.43
In addition to the annotated Plasmodium genes, there are
many genes that have not been annotated, the so-called
hypothetical proteins. There may well be attractive targets,
which could be very different structurally and functionally from
human proteins, potentially allowing for selective inhibitors. It
is also important to consider that the definition of druggability,
for this exercise, is dependent on the existence of ligand-bound
protein structures in the Protein Data Bank (https://www.
rcsb.org/). Proteins that are more difficult to structurally
characterize, such as membrane proteins, may have been
overlooked. Paradoxically, the more different a Plasmodium
protein is from its mammalian ortholog, the more likely it is to
not be recognized as druggable. Another important consid-
eration is that there may be nonprotein targets, including
rRNAs. Compounds that target the bacterial-type protein
biosynthesis machinery, including azithromycin, clindamycin,
and tetracycline, have antimalarial activity, although many have
a slow rate of kill.
While the focus of this exercise has been to prioritize
potential targets for drug discovery, this process will have
considerable value in further dissecting the fundamental
biology of these parasites. Understanding the biological context
of a target is key to understanding how a potential drug target
may be exploited in the clinic. Further, since all antimalarials
are now given as combination therapies, understanding the
background biology is important in selecting combinations.
Even for targets that are not deemed suitable from a drug
discovery context, this exercise can still provide valuable
biological insights into these important pathogens.
One aim of this publication is to stimulate discovery and
validation of potential new drug targets for Plasmodium. We
hope that it will facilitate efforts in the broader malaria
community writ large to continue to contribute valuable
insights to support the antimalarial drug development effort.
We welcome comments from the community on these and
other targets. To that end, we invite comments on our Web
site (www.malariaDA.org), which will then be used to annotate
a list of potential targets, to be displayed on the Web site.
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